Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription

Articles published in Anticancer Drugs

Retrieve available abstracts of 11 articles:
HTML format
Text format

Single Articles

    November 2017
  1. LV KT, Gao LJ, Hua X, Li F, et al
    The role of the globular heads of the C1q receptor in paclitaxel-induced human ovarian cancer cells apoptosis by a mitochondria-dependent pathway.
    Anticancer Drugs. 2017 Nov 23. doi: 10.1097/CAD.0000000000000567.
    PubMed     Text format     Abstract available

    September 2017
  2. ASSI T, Kourie HR, El Rassy E, Moussa T, et al
    Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole.
    Anticancer Drugs. 2017;28:931-933.
    PubMed     Text format     Abstract available

    August 2017
  3. REEVES PM, Abbaslou MA, Kools FRW, Poznansky MC, et al
    CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
    Anticancer Drugs. 2017 Aug 16. doi: 10.1097/CAD.0000000000000518.
    PubMed     Text format     Abstract available

    July 2017
  4. BORASKA JELAVIC T, Boban T, Brcic L, Vrdoljak E, et al
    Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
    Anticancer Drugs. 2017 Jul 3. doi: 10.1097/CAD.0000000000000538.
    PubMed     Text format     Abstract available

    May 2017
  5. PENDLEBURY A, DeBernardo R, Rose PG
    Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
    Anticancer Drugs. 2017 May 24. doi: 10.1097/CAD.0000000000000521.
    PubMed     Text format     Abstract available

    April 2016
  6. AYYAGARI VN, Johnston NA, Brard L
    Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.
    Anticancer Drugs. 2016.
    PubMed     Text format     Abstract available

  7. AWADA A, Campone M, Varga A, Aftimos P, et al
    An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
    Anticancer Drugs. 2016;27:342-8.
    PubMed     Text format     Abstract available

    March 2016
  8. BROUGHTON LJ, Crow C, Maraveyas A, Madden LA, et al
    Duramycin-induced calcium release in cancer cells.
    Anticancer Drugs. 2016;27:173-82.
    PubMed     Text format     Abstract available

    November 2015
  9. GOUNARIS I, Iddawela M, Parkinson C, Pratt J, et al
    Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: Too toxic for relapse?
    Anticancer Drugs. 2015.
    PubMed     Text format     Abstract available

    August 2015
  10. ZHANG Y, Guo G, Ma B, Du R, et al
    A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
    Anticancer Drugs. 2015;26:698-705.
    PubMed     Text format     Abstract available

    June 2015
  11. ZHANG H, Jing X, Wu X, Hu J, et al
    Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
    Anticancer Drugs. 2015.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.